Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931059 · ClinicalTrials.gov registry record · NA
Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01931059: Completed NA study, sponsored by Northwell Health.
NCT01931059 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01931059, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
To detect the effect of second-generation antipsychotic drug on the neural activity.
Primary Outcome
This will measure the subject's cognitive performance. RBANS is a well-characterized repeatable battery to measure a wide array of cognitive performance in different cognitive domains. We will use Total Score in RBANS: five index scores are computed from the RBANS (immediate memory, language, visuospatial, attention, delayed memory) that are combined to provide the Total Score. The Total Score is expressed as a standardized score normalized to a population mean of 100, with a standard deviation
Interventions
- OTHER Placebo
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-07 |
| Phase | NA |
What the finished NCT01931059 record still lists
NCT01931059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01931059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01931059 about?
NCT01931059 is a clinical study titled "Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers". To detect the effect of second-generation antipsychotic drug on the neural activity.
What is the current status of trial NCT01931059?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2013-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01931059?
The interventions under investigation include: Placebo (OTHER), Risperidone (DRUG).
Who is sponsoring clinical trial NCT01931059?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01931059's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia